Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies
Ilaria Attili, Marzia Del Re, Elena Guerini‐Rocco, et al.
Expert Review of Molecular Diagnostics (2021) Vol. 21, Iss. 8, pp. 757-766
Closed Access | Times Cited: 9

Showing 9 citing articles:

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
Carla Corvaja, Antonio Passaro, Ilaria Attili, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102824-102824
Closed Access | Times Cited: 13
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer
Umberto Malapelle, Pasquale Pisapia, Alfredo Addeo, et al.
Expert Review of Molecular Diagnostics (2021) Vol. 21, Iss. 11, pp. 1165-1178
Closed Access | Times Cited: 42
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Ilaria Attili, Antonio Passaro, Carla Corvaja, et al.
Cancer Treatment Reviews (2023) Vol. 119, pp. 102602-102602
Closed Access | Times Cited: 19
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5079-5079
Open Access | Times Cited: 16
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2589-2589
Open Access | Times Cited: 4
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)
Cesare Gridelli, Tony Mok, Pasi A. Jänne, et al.
Lung Cancer (2025) Vol. 201, pp. 108100-108100
Closed Access
miR-30a-5p/PHTF2 axis regulates the tumorigenesis and metastasis of lung adenocarcinoma
Lijuan Zhang, QINGYIN MENG, Li Zhuang, et al.
Biocell (2024) Vol. 48, Iss. 4, pp. 581-590
Open Access | Times Cited: 2
Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis
Ilaria Attili, Riccardo Asnaghi, Davide Vacirca, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 15, pp. 4476-4476
Open Access | Times Cited: 2
Recent Updates on Structural Aspects of ALK Inhibitors as an Anticancer Agent
Vivek Asati, Md Shahid Ayaz, Ritu Bhupal, et al.
Anti-Cancer Agents in Medicinal Chemistry (2023) Vol. 23, Iss. 8, pp. 900-921
Closed Access | Times Cited: 3
Page 1

Scroll to top